"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 9 | 1 | 10 |
| 1997 | 27 | 11 | 38 |
| 1998 | 44 | 17 | 61 |
| 1999 | 47 | 18 | 65 |
| 2000 | 61 | 18 | 79 |
| 2001 | 54 | 20 | 74 |
| 2002 | 63 | 19 | 82 |
| 2003 | 57 | 25 | 82 |
| 2004 | 55 | 31 | 86 |
| 2005 | 58 | 24 | 82 |
| 2006 | 68 | 28 | 96 |
| 2007 | 75 | 32 | 107 |
| 2008 | 80 | 32 | 112 |
| 2009 | 73 | 29 | 102 |
| 2010 | 88 | 36 | 124 |
| 2011 | 108 | 52 | 160 |
| 2012 | 111 | 43 | 154 |
| 2013 | 108 | 29 | 137 |
| 2014 | 114 | 39 | 153 |
| 2015 | 126 | 32 | 158 |
| 2016 | 120 | 58 | 178 |
| 2017 | 118 | 50 | 168 |
| 2018 | 126 | 47 | 173 |
| 2019 | 137 | 51 | 188 |
| 2020 | 170 | 40 | 210 |
| 2021 | 149 | 20 | 169 |
| 2022 | 110 | 3 | 113 |
| 2023 | 96 | 4 | 100 |
| 2024 | 92 | 72 | 164 |
| 2025 | 3 | 5 | 8 |
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study. PLoS One. 2025; 20(2):e0319010.
-
Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment. J Int AIDS Soc. 2025 Feb; 28(2):e26422.
-
Correlates of internalized stigma and antiretroviral therapy adherence among people living with HIV in the Volta region of Ghana. BMC Public Health. 2025 Jan 27; 25(1):342.
-
'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa. HIV Res Clin Pract. 2025 Dec; 26(1):2455917.
-
Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV. Sci Adv. 2025 Jan 24; 11(4):eads1911.
-
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084. J Int AIDS Soc. 2025 Jan; 28(1):e26401.
-
Community Perspectives on Optimizing Community Health Volunteer Roles for HIV Prevention Services in Kenya and Uganda. AIDS Patient Care STDS. 2025 Jan; 39(1):21-31.
-
Update on HIV Chemoprevention. Annu Rev Med. 2025 Jan; 76(1):43-56.
-
Acceptability and feasibility of a urine-based tenofovir adherence assay for monitoring and providing feedback on PrEP adherence in Kenya. AIDS Care. 2025 Feb; 37(2):324-336.
-
Randomized Pilot Trial of the Text-Based Adherence Game for Ghanaian Youth with HIV. AIDS Behav. 2025 Mar; 29(3):791-803.